参考文献/References:
[1]Donmez G,Outeiro TF.SIRT1 and SIRT2:Emerging Targets in Neurodegeneration[J].EMBO Mol Med,2013,5(3):344-352.
[2]张现营.去乙酰化酶Sirt2参与脂类代谢研究[D].华东师范大学,2015.
[3]Masri S.Sirtuin-Dependent Clock Control:New Advances in Metabolism, Aging and Cancer[J].Curr Opin Clin Nutr Metab Care,2015,18(6):521-527.
[4]Vaquero A,Scher MB,Lee DH,et al.SirT2 is a Histone Deacetylase with Preference for Histone H4 Lys 16 During Mitosis[J].Genes Dev,2006,20(10):1256-1261.
[5]North BJ,Verdin E.Interphase Nucleo-Cytoplasmic Shuttling and Localization of SIRT2 During Mitosis[J].PLoS One,2007,2(8):e784.
[6]Dryden SC,Nahhas FA,Nowak JE,et al.Role for Human SIRT2 NAD-dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle[J].Mol Cell Biol,2003,23(9):3173-3185.
[7]吴国芳,路宏朝,贾龙,等.干扰Sirt2促进C2C12成肌细胞分化[J].中国生物化学与分子生物学报,2014,30(7):714-720.
[8]Eijkelenboom A,Burgering BM.FOXOs:Signalling Integrators for Homeostasis Maintenance[J].Nat Rev Mol Cell Biol,2013,14(2):83-97.
[9]Gomes P,Fleming OT,Cavadas C.Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism[J].Trends Pharmacol Sci,2015,36(11):756-768.
[10]Wang F,Tong Q.SIRT2 Suppresses Adipocyte Differentiation by Deacetylating FOXO1 and Enhancing FOXO1’s Repressive Interaction with PPARgamma[J].Mol Biol Cell,2009,20(3):801-808.
[11]Jiang W,Wang S,Xiao M,et al.Acetylation Regulates Gluconeogenesis by Promoting PEPCK1 Degradation Via Recruiting the UBR5 Ubiquitin Ligase[J].Mol Cell,2011,43(1):33-44.
[12]杜燕华,张海燕,孙红.Sirt2在浆液性卵巢癌细胞系中的表达及其对增殖、迁移和侵袭的影响[J].中国病理生理杂志,2015,31(7):1209-1213.
[13]Kim HS,Vassilopoulos A,Wang RH,et al.SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity[J].Cancer Cell,2011,20(4):487-499.
[14]Inoue T,Hiratsuka M,Osaki M,et al.The Molecular Biology of Mammalian SIRT Proteins: SIRT2 in Cell Cycle Regulation[J].Cell Cycle,2007,6(9):1011-1018.
[15]Li Y,Zhang M,Dorfman RG,et al.SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism[J].Neoplasia,2018,20(7):745-756.
[16]Liu PY,Xu N,Malyukova A,et al.The Histone Deacetylase SIRT2 Stabilizes Myc Oncoproteins[J].Cell Death Differ,2013,20(3):503-514.
[17]宋春丽,任吉华,冉龙宽,等.Sirt2沉默对肝癌细胞的迁移和侵袭能力的影响[J].第三军医大学学报,2013,35(24):2634-2638.
[18]王平安.剪接因子Srsf2在肝细胞癌中的作用及Sirt2在肝内胆管癌发生发展中的作用及机制研究[D].山东大学,2018.
[19]Peck B,Chen CY,Ho KK,et al.SIRT Inhibitors Induce Cell Death and P53 Acetylation through Targeting Both SIRT1 and SIRT2[J].Mol Cancer Ther,2010,9(4):844-855.
[20]Kastenhuber ER,Lowe SW.Putting P53 in Context[J].Cell,2017,170(6):1062-1078.
[21]Yue X,Zhao Y,Xu Y,et al.Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy[J].J Mol Biol,2017,429(11):1595-1606.
[22]Rinkenbaugh AL,Baldwin AS.The NF-κB Pathway and Cancer Stem Cells[J].Cells,2016,5(2):E16.
[23]Giampazolias E,Zunino B,Dhayade S,et al.Mitochondrial Permeabilization Engages NF-κB-dependent Anti-Tumour Activity Under Caspase Deficiency[J].Nat Cell Biol,2017,19(9):1116-1129.
[24]吴安定,万里鹏,覃艳琼.结直肠腺癌组织中Cyr61和NF-κB P65的表达及其临床病理意义[J].世界华人消化杂志,2018,26(17):1056-1063.
[25]Chen L,Fischle W,Verdin E,et al.Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation[J].Science,2001,293(5535):1653-1657.
[26]Kiernan R,Bres V,Ng RW,et al.Post-Activation Turn-Off of NF-κB-dependent Transcription is Regulated by Acetylation of P65[J].J Biol Chem,2003,278(4):2758-2766.
[27]Zhou S,Tang X,Chen HZ.Sirtuins and Insulin Resistance[J].Front Endocrinol(Lausanne),2018(9):748.
[28]Paik JH,Kollipara R,Chu G,et al.FoxOs are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis[J].Cell,2007,128(2):309-323.
[29]Jing E,Gesta S,Kahn CR.SIRT2 Regulates Adipocyte Differentiation through FoxO1 Acetylation/Deacetylation[J].Cell Metab,2007,6(2):105-114.
[30]Zhao Y,Yang J,Liao W,et al.Cytosolic FoxO1 is Essential for the Induction of Autophagy and Tumour Suppressor Activity[J].Nat Cell Biol,2010,12(7):665-675.
[31]Du Y,Wu J,Zhang H,et al.Reduced Expression of SIRT2 in Serous Ovarian Carcinoma Promotes Cell Proliferation through Disinhibition of CDK4 Expression[J].Mol Med Rep,2017,15(4):1638-1646.
[32]刘伟,肖俊,兰金芝,等.组蛋白乙酰化水平对肝癌细胞迁移和侵袭能力的影响[J].贵州医科大学学报,2017,42(12):1365-1369.
[33]Das C,Lucia MS,Hansen KC,et al.CBP/p300-mediated Acetylation of Histone H3 On Lysine 56[J].Nature,2009,459(7243):113-117.
[34]Serrano L,Martinez-Redondo P,Marazuela-Duque A,et al.The Tumor Suppressor SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating the Mitotic Deposition of H4K20 Methylation[J].Genes Dev,2013,27(6):639-653.
[35]石斌,王昊,赵亮,等.组蛋白去乙酰化酶抑制剂对肺癌细胞株Mdr1、Mrp1表达的影响及其机制[J].山东医药,2018(39):13-16.
[36]Ebeid K,Meng X,Thiel KW,et al.Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer[J].Nature Nanotechnology,2018,13(1):72-81.
[37]Tran A,Gehrig P.Recent Advances in Endometrial Cancer[J].F1000Research,2017(6):81.
[38]Chen W,Zheng R,Baade PD,et al.Cancer Statistics in China, 2015[J].CA: A Cancer Journal for Clinicians,2016,66(2):115-132.
[39]谢幸.妇产科学[M].第8版.北京:人民卫生出版社,2014:488.
[40]Practice Bulletin No.149: Endometrial Cancer[J].Obstet Gynecol,2015,125(4):1006-1026.
[41]王艺霖.SIRTl/FoxOl/SREBP-1通路在子宫内膜癌孕激素抵抗发展中的作用[D].山东大学,2018.
相似文献/References:
[1]单菲菲,陈 琴,吕建国,等.体力活动与子宫内膜癌关系的病例对照研究[J].医学信息,2018,31(10):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
SHAN Fei-fei,CHEN Qin,LV Jian-guo,et al.Case Control Study on the Relationship between Physical Activity and Endometrial Carcinoma[J].Medical Information,2018,31(05):62.[doi:10.3969/j.issn.1006-1959.2018.10.019]
[2]杨 帆.纽曼系统护理模式对降低子宫内膜癌患者子宫全切术后焦虑抑郁情绪的效果研究[J].医学信息,2022,35(09):184.[doi:10.3969/j.issn.1006-1959.2022.09.048]
YANG Fan.Effect of Newman System Nursing Mode on Reducing Anxiety and Depression in Patients with Endometrial Carcinoma After Total Hysterectomy[J].Medical Information,2022,35(05):184.[doi:10.3969/j.issn.1006-1959.2022.09.048]
[3]季福水.AP-4、EZH2基因表达量与子宫内膜癌病灶中细胞凋亡、
上皮间质转化的相关性研究[J].医学信息,2018,31(14):92.[doi:10.3969/j.issn.1006-1959.2018.14.026]
JI Fu-shui.Correlation between AP-4 and EZH2 Gene Expression Levels and Apoptosis and Epithelial-mesenchymal Transition in Endometrial Cancer[J].Medical Information,2018,31(05):92.[doi:10.3969/j.issn.1006-1959.2018.14.026]
[4]吴昭怡,黄金智,张庆余,等.靶向PI3K/AKT/mTOR通路治疗子宫内膜癌的研究现状[J].医学信息,2022,35(12):68.[doi:10.3969/j.issn.1006-1959.2022.12.016]
WU Zhao-yi,HUANG Jin-zhi,ZHANG Qing-yu,et al.Research Status of Targeted PI3K/AKT/mTOR Pathway in the Treatment of Endometrial Carcinoma[J].Medical Information,2022,35(05):68.[doi:10.3969/j.issn.1006-1959.2022.12.016]
[5]罗婵娟.子宫内膜癌组织中miR-143的表达及与预后的相关性分析[J].医学信息,2022,35(15):75.[doi:10.3969/j.issn.1006-1959.2022.15.016]
LUO Chan-juan.Expression of miR-143 in Endometrial Carcinoma Tissues and its Correlation with Prognosis[J].Medical Information,2022,35(05):75.[doi:10.3969/j.issn.1006-1959.2022.15.016]
[6]帅纬纬,谢利莎,朱 萍.不同护理方式对子宫内膜癌化疗患者负性情绪及生活质量的影响[J].医学信息,2019,32(21):178.[doi:10.3969/j.issn.1006-1959.2019.21.061]
SHUAI Wei-wei,XIE Li-sha,ZHU Ping.Effects of Different Nursing Methods on Negative Emotion and Quality of Life in Patients with Endometrial Cancer Chemotherapy[J].Medical Information,2019,32(05):178.[doi:10.3969/j.issn.1006-1959.2019.21.061]
[7]彭端龙,黄 浩.早期子宫内膜癌诊疗研究[J].医学信息,2020,33(01):51.[doi:10.3969/j.issn.1006-1959.2020.01.017]
PENG Duan-long,HUANG Hao,et al.Research on Diagnosis and Treatment of Early Endometrial Cancer[J].Medical Information,2020,33(05):51.[doi:10.3969/j.issn.1006-1959.2020.01.017]
[8]张晓黎,张 颖,陈国通,等.环状RNA在妇科恶性肿瘤中的研究进展[J].医学信息,2020,33(03):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
ZHANG Xiao-li,ZHANG Ying,CHEN Guo-tong,et al.Study of Circular RNA in Gynecological Malignancies[J].Medical Information,2020,33(05):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
[9]谭晓瑜,黄金智,赖锦胜,等.SP/NK-1R及其与子宫内膜癌的关系[J].医学信息,2020,33(07):29.[doi:10.3969/j.issn.1006-1959.2020.07.010]
TAN Xiao-yu,HUANG Jin-zhi,LAI Jin-sheng,et al.Study on SP/NK-1R and Its Relationship with Endometrial Cancer[J].Medical Information,2020,33(05):29.[doi:10.3969/j.issn.1006-1959.2020.07.010]
[10]荐桂丽,任玉环.血清HE4、CA125在子宫内膜癌中的研究[J].医学信息,2021,34(02):53.[doi:10.3969/j.issn.1006-1959.2021.02.015]
JIAN Gui-li,REN Yu-huan.Study on Serum HE4 and CA125 in Endometrial Cancer[J].Medical Information,2021,34(05):53.[doi:10.3969/j.issn.1006-1959.2021.02.015]